[an error occurred while processing this directive] | [an error occurred while processing this directive]
Advances and the status of radiotherapy in advanced esophageal cancer
Chen Mingyue1, Jie Wei2, Zhou Zhiguo3, Wang Jun3, Bai Wenwen3, Zhen Chanjun3, Zhang Ping3
1Department of Radiation Oncology, National Cancer Center / National Clinical Research Center for Cancer / Hebei Cancer Hospital, Chinese Academy of Medical Sciences, Langfang 065001, China; 2Department of Radiation Oncology, Baoji Central Hospital, Baoji 721008, China; 3Department of Radiation Oncology, the Fourth Hospital of Hebei Medical University, Shijiazhuang 050000, China
Abstract Radiotherapy plays an important role in the treatment of advanced esophageal cancer. Under the premise of effective systemic treatment, selecting patients who may benefit from local radiotherapy can effectively relieve symptoms and improve quality of life, and it is expected to prolong the survival time of patients. Moreover, immunotherapy plays an increasingly significant role in advanced esophageal cancer, and the efficacy of radiotherapy combined with immunotherapy is promising.
Chen Mingyue,Jie Wei,Zhou Zhiguo et al. Advances and the status of radiotherapy in advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(6): 562-566.
Chen Mingyue,Jie Wei,Zhou Zhiguo et al. Advances and the status of radiotherapy in advanced esophageal cancer[J]. Chinese Journal of Radiation Oncology, 2023, 32(6): 562-566.
[1] Chen WQ, Zheng RS, Zeng HM, et al.The incidence and mortality of major cancers in China, 2012[J]. Chin J Cancer, 2016,35(1):73. DOI: 10.1186/s40880-016-0137-8. [2] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018,68(6):394-424. DOI: 10.3322/caac.21492. [3] Lin YS, Totsuka Y, He YT, et al.Epidemiology of esophageal cancer in Japan and China[J]. J Epidemiol, 2013,23(4):233-242. DOI: 10.2188/jea.je20120162. [4] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007[J]. CA Cancer J Clin, 2007,57(1):43-66. DOI:10.1002/caac.20073. [5] Nieman DR, Peters JH.Treatment strategies for esophageal cancer[J]. Gastroenterol Clin North Am, 2013,42(1):187-197. DOI: 10.1016/j.gtc.2012.11.007. [6] Ai DS, Zhu HT, Ren WJ, et al.Patterns of distant organ metastases in esophageal cancer: a population-based study[J]. J Thorac Dis, 2017,9(9):3023-3030. DOI: 10.21037/jtd.2017.08.72. [7] Zhang YW.Epidemiology of esophageal cancer[J]. World J Gastroenterol, 2013,19(34):5598-5606. DOI: 10.3748/wjg.v19.i34.5598. [8] Tanaka T, Fujita H, Matono S, et al.Outcomes of multimodality therapy for stage IVB esophageal cancer with distant organ metastasis (M1-Org)[J]. Dis Esophagus, 2010,23(8):646-651. DOI: 10.1111/j.1442-2050.2010.01069.x. [9] Cunningham D, Starling N, Rao S, et al.Capecitabine and oxaliplatin for advanced esophagogastric cancer[J]. N Engl J Med, 2008,358(1):36-46. DOI:10.1056/NEJMoa073149. [10] NCCN. The NCCN esophageal and esophagogastric junction cancers clinical practice guidelines in oncology (version 4.2021)[EB/OL]. Fort Washington: NCCN, 2021. [2021-10-20]. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. [11] Halpern AL, McCarter MD. Palliative management of gastric and esophageal cancer[J]. Surg Clin North Am, 2019,99(3):555-569. DOI: 10.1016/j.suc.2019.02.007. [12] Lin CY, Fang HY, Lein MY, et al.Clinical outcomes and prognostic factors of patients with esophageal squamous cell carcinoma with oligo-recurrence treated with radical re-irradiation[J]. Anticancer Res, 2020,40(4):2387-2392. DOI: 10.21873/anticanres.14208. [13] Quint LE, Hepburn LM, Francis IR, et al. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma[J]. Cancer, 1995,76(7):1120-1125. DOI: 10.1002/1097-0142(19951001)76:7<1120::aid-cncr2820760704>3.0.co;2-w. [14] Domper Arnal MJ, Ferrández AÁ, Lanas AÁ.Esophageal cancer: risk factors, screening and endoscopic treatment in western and eastern countries[J]. World J Gastroenterol, 2015,21(26):7933-7943. DOI: 10.3748/wjg.v21.i26.7933. [15] Rice TW, Patil DT, Blackstone EH.8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice[J]. Ann Cardiothorac Surg, 2017,6(2):119-130. DOI: 10.21037/acs.2017.03.14. [16] Short MW, Burgers KG, Fry VT.Esophageal cancer[J]. Am Fam Physician, 2017,95(1):22-28. [17] Lyu JH, Li T, Wang QF, et al.Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for stage IV esophageal squamous cell carcinoma: a retrospective controlled study[J]. Radiat Oncol, 2018,13(1):233. DOI: 10.1186/s13014-018-1183-y. [18] Xu J, Lu DH, Zhang L, et al.Palliative resection or radiation of primary tumor prolonged survival for metastatic esophageal cancer[J]. Cancer Med, 2019,8(17):7253-7264. DOI: 10.1002/cam4.2609. [19] Chen YS, Cheng XY, Song HX, et al.Outcomes of concurrent chemoradiotherapy versus chemotherapy alone for esophageal squamous cell cancer patients presenting with oligometastases[J]. J Thorac Dis, 2019,11(4):1536-1545. DOI: 10.21037/jtd.2019.03.10. [20] 殷蔚伯, 张力军, 杨宗贻, 等. 放射治疗食管癌3,798例临床分析[J].中华肿瘤杂志,1980,2(3):216-221. Yin WB, Zhang LJ, Yang ZY, et al. Clinical analysis of 3,798 cases of esophageal cancer treated with radiotherapy[J]. Chin J Oncol,1980,2(3):216-221. [21] Okawa T, Kita M, Tanaka M, et al.Results of radiotherapy for inoperable locally advanced esophageal cancer[J]. Int J Radiat Oncol Biol Phys, 1989,17(1):49-54. DOI: 10.1016/0360-3016(89)90369-6. [22] 孙联亭, 赵瑞芬, 张佩怀, 等. 495例食管癌伴锁骨上淋巴结转移的临床分析[J].中华放射肿瘤学杂志,1991,(2):34-36. Sun LT, Zhao RF, Zhang PH, et al.Clinical analysis of 495 cases of esophageal carcinoma with supraclavicular lymph node metastasis[J].Chin J Radiat Oncol,1991,(2):34-36. [23] 章耀鸿, 唐喜军, 陶瑞康, 等. 食管癌术后局部区域复发的治疗的疗效分析[J].中华放射肿瘤学杂志,2003,12(2):89-91. DOI: 10.3760/j.issn:1004-4221.2003.02.004. Zhang YH, Tang XJ, Tao RK, et al.Treatment of loco-recurrence after resection of esophageal carcinoma[J]. Chin J Radiat Oncol,2003,12(2):89-91. DOI: 10.3760/j.issn:1004-4221.2003.02.004. [24] 周绍兵, 刘阳晨, 项其昌, 等. 放疗、化疗治疗食管癌伴锁骨上区淋巴结转移的临床分析[J].实用癌症杂志,2002,17(1):95-96. DOI: 10.3969/j.issn.1001-5930.2002.01.036. Zhou SB, Liu YC, Xiang QC, et al. Clinical analysis of radiotherapy and chemotherapy for esophageal cancer with supraclavicular lymph node metastasis[J]. Chin J Prac Cancer,2002,17(1):95-96. DOI:10.3969/j.issn.1001-5930.2002.01.036. [25] 吴剑, 卢晓红. 食管癌伴锁骨上淋巴结转移的放射治疗[J].中国医刊,2008,43(12):59-60. DOI: 10.3969/j.issn.1008-1070.2008.12.024. Wu J, Lu XH. Radiotherapy for esophageal carcinoma with supraclavicular lymph node metastasis[J]. Chin Med J,2008,43(12):59-60. DOI:10.3969/j.issn.1008-1070.2008.12.024. [26] 甄婵军, 周志国, 宋玉芝, 等. 食管癌锁骨上淋巴结转移放疗疗效及预后因素分析[J]. 肿瘤防治研究,2013,40(01):90-94. DOI:10.3971/j.issn.1000-8578.2013.01.023. Zhen CJ, Zhou ZG, Song YZ, et al. Effect of radiotherapy on esophageal carcinoma with supraclavicular lymph node metastasis and prognostic factors[J]. Cancer Prev Treat Res,2013,40(1):90-94. DOI:10.3971/j.issn.1000-8578.2013.01.023. [27] Siva S, MacManus MP, Martin RF, et al. Abscopal effects of radiation therapy: a clinical review for the radiobiologist[J]. Cancer Lett, 2015,356(1):82-90. DOI: 10.1016/j.canlet.2013.09.018. [28] Weiss EM, Wunderlich R, Ebel N, et al.Selected anti-tumor vaccines merit a place in multimodal tumor therapies[J]. Front Oncol, 2012,2:132. DOI: 10.3389/fonc.2012.00132. [29] 贺蓓娃, 赵于天, 章国芬, 等. 60例晚期食管癌放疗+射频热疗+免疫治疗的近期疗效分析[J].江南大学学报(自然科学版),2002,1(4):425-428. DOI: 10.3969/j.issn.1671-7147.2002.04.026. He BW, Zhao YT, Zhang GF, et al.An evaluation of short-term clinical effectiveness in the treatment of advanced esophageal carcinoma with radiotherapy, radio-frequency hyperthermia and immunotherapy[J]. Journal Of Southern Yangtze University (Natural Science Edition),2002,1(4):425-428. DOI: 10.3969/j.issn.1671-7147.2002.04.026. [30] Deng LF, Liang H, Burnette B, et al.Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice[J]. J Clin Invest, 2014,124(2):687-695. DOI: 10.1172/JCI67313.
2023, Vol. 32 
